Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-interleukin 21 monoclonal antibody - Novo Nordisk

Drug Profile

Anti-interleukin 21 monoclonal antibody - Novo Nordisk

Alternative Names: Anti-IL21-Novo-Nordisk; NN-8828; NN-9828; NNC-0114-0000-0005; NNC0114-0006; NNC114-0005

Latest Information Update: 21 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 21 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus

Most Recent Events

  • 21 Feb 2024 9410245- Created deal 37240, linked to profile, updated intro, added as sub-licensee, added HE. Indication taken as mentioned in MR as no specific indication was mentioned as per thes. Almirall Pipeline checked, but no info found except this MR
  • 19 Feb 2024 NN 8828 licensed to Almirall worldwide for the treatment of Immune inflammatory dermatological diseases
  • 30 Oct 2020 Discontinued - Phase-II for Type 1 diabetes mellitus (Combination therapy, Newly diagnosed) in Poland, Belgium, United Kingdom, Denmark, Sweden, Ukraine, Spain, Serbia, Russia, Portugal, Norway, Italy, Israel, Ireland, Finland, Canada, Austria, USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top